본문 바로가기 주메뉴 바로가기

제품소개

제품상세페이지

Proteogenix

[Proteogenix] Anti-RBD-5 antibody (Imdevimab)

Cat-No. PTXCOV-A553


Proteogenix는 Primary Antibody Biosimilar - Research Grade 

제품을 전문적으로 생산하는 20년의 경험이 있는 High Quality 제조사입니다.




제품 설명 


Anti-RBD-5 antibody (Imdevimab)

  



제품 번호

 

PTXCOV-A553

 



제품 특징


Product nameAnti-RBD-5 antibody (Imdevimab)
SpeciesHuman
Expression systemMammalian
Molecular weight150kDa
Purity85%
BufferPBS, pH7,5
FormLiquid
Delivery conditionBlue ice (+4°C)
Storage condition4°C for short term; -20°c or -80°C for long term
BrandProteoGenix
Host speciesMouse
Aliases /SynonymsREGN10987
ReferencePTXCOV-A553
NoteFor research use only. Not suitable for human use.
IsotypeIgG1
ClonalityMonoclonal Antibody
TargetRBD domain- SARS-CoV2 Spike protein for first type and variants (PX-COV-P046, PX-COV-P052, PX-COV-P053, PX-COV-P054, PX-COV-P056)
Target speciesSARS-CoV-2


Description of Anti-RBD-5 antibody (Imdevimab)

General information on Anti-RBD-5 antibody

The anti-CoV-RBD antibody is an anti-SARS-CoV-2 antibody with potential neutralizing activity. By screening its receptor-binding domain (RBD), extensive library of COVID-19 antibodies (LiAb-SFCOVID-19 *) identify the new coronavirus. Variants produced in IgG format have shown stable stability when expressed in XtenCHO ™ (transient expression system based on the created cell line) and consistently provide high and consistent amounts.
In an ELISA (enzyme-linked immunosorbent assay) plate, the specificity and affinity of the IgG antibody were tested against the purified and recombinant form of RBD. Furthermore, the SARS-CoV-2 alternative virus neutralization test (sVNT) indirectly confirmed the neutralization ability. This test is designed to quickly and accurately detect the ability of antibody variants to block the interaction between RBD and specific human receptors. ACE2.
Since the beginning of the pandemic, many studies have confirmed the therapeutic potential of SARS-CoV-2 NAb (neutralizing antibody). The reason RBD takes precedence over other SARS-CoV-2 domains is its key role in the emergence of viral infections. By preventing this important interaction, the researchers hope to halt the development of the disease. Antibody therapy also shows unique advantages over small molecules in the treatment of COVID-19. In fact, most antiviral medications suppress the immune response, which generally delays the clearance of virus particles from the patient. In contrast, antibody therapy further engages and activates the individual’s immune system, resulting in a synergy between the blocking activity of the antibodies and a faster and safer removal of virus pathogens. In this case, the investigation of neutralizing antibodies (such as anti-CoV-RBD (E4)) can help to investigate the progression of the disease and the response of the body to specific therapies.




QC & Validation Data


SDS-PAGE for Anti-RBD-5 antibody

Anti-RBD-5 antibody (Imdevimab), on SDS-PAGE under reducing and non-reducing conditions. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.




Publications


  • Fiedler, S., Devenish, S.R.A., Morgunov, A.S. et al. Serological fingerprints link antiviral activity of therapeutic antibodies to affinity and concentration. Sci Rep 12, 19791 (2022). https://doi.org/10.1038/s41598-022-22214-z




ProteoGenix의 모든 제품들을 만나보세요!

 

Proteogenix - Exclusive Distributor in South Korea "Morebio" 한국 독점 대리점 "모아바이오"